Health
Inhibrx reports early cancer immunotherapy responses targeting the OX40 protein
STAT reports that positive trial results were concentrated in a narrow patient group.
The short version
- Inhibrx announced clinical responses in head and neck cancer patients using an experimental OX40 immunotherapy.[STAT]
- The strongest efficacy appeared in a small group of HPV-positive cases, potentially narrowing its clinical scope.[STAT]
- Multiple major pharmaceutical firms previously failed to develop effective OX40 therapies over the last 15 years.[STAT]
Key facts
- Inhibrx reported positive responses in head and neck cancer patients treated with its experimental OX40-targeting immunotherapy.[STAT]
- The strongest responses were observed within a small subset of patients having HPV-positive tumors.[STAT]
- Prior efforts to target OX40 over 15 years by companies such as Pfizer, Genentech, GSK, and AstraZeneca ended in failure.[STAT]
What remains uncertain
- It remains unclear whether the therapy will prove effective beyond the narrow subset of HPV-positive cancer patients.[STAT]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.